Regenxbio Inc has a consensus price target of $41.21, established from looking at the 43 latest analyst ratings. The last 3 analyst ratings were released from Stifel, HC Wainwright & Co., and RBC Capital on April 12, 2024, March 11, 2024, and March 8, 2024. With an average price target of $37 between Stifel, HC Wainwright & Co., and RBC Capital, there's an implied 133.29% upside for Regenxbio Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
04/12/2024 | RGNX | Buy Now | Regenxbio | $15.86 | 152.21% | Stifel | Annabel Samimy | → $40 | Maintains | Buy | Get Alert |
03/11/2024 | RGNX | Buy Now | Regenxbio | $15.86 | 126.99% | HC Wainwright & Co. | Yi Chen | → $36 | Initiates | → Buy | Get Alert |
03/08/2024 | RGNX | Buy Now | Regenxbio | $15.86 | 120.68% | RBC Capital | Luca Issi | $20 → $35 | Upgrade | Sector Perform → Outperform | Get Alert |
03/07/2024 | RGNX | Buy Now | Regenxbio | $15.86 | 227.87% | Chardan Capital | Daniil Gataulin | $52 → $52 | Maintains | Buy | Get Alert |
03/07/2024 | RGNX | Buy Now | Regenxbio | $15.86 | 246.78% | Barclays | Gena Wang | $45 → $55 | Maintains | Overweight | Get Alert |
03/06/2024 | RGNX | Buy Now | Regenxbio | $15.86 | — | Leerink Partners | Mani Foroohar | — | Upgrade | Market Perform → Outperform | Get Alert |
03/06/2024 | RGNX | Buy Now | Regenxbio | $15.86 | 145.9% | Baird | Brian Skorney | $34 → $39 | Maintains | Outperform | Get Alert |
02/28/2024 | RGNX | Buy Now | Regenxbio | $15.86 | 32.41% | Wedbush | Andreas Argyrides | → $21 | Reiterates | Neutral → Neutral | Get Alert |
02/21/2024 | RGNX | Buy Now | Regenxbio | $15.86 | 183.73% | Raymond James | Dane Leone | → $45 | Reinstates | → Outperform | Get Alert |
02/12/2024 | RGNX | Buy Now | Regenxbio | $15.86 | 32.41% | Wedbush | Andreas Argyrides | → $21 | Reiterates | Neutral → Neutral | Get Alert |
11/01/2023 | RGNX | Buy Now | Regenxbio | $15.86 | 120.68% | Stifel | Annabel Samimy | → $35 | Initiates | → Buy | Get Alert |
10/05/2023 | RGNX | Buy Now | Regenxbio | $15.86 | 26.1% | Wedbush | Andreas Argyrides | → $20 | Reiterates | Neutral → Neutral | Get Alert |
10/04/2023 | RGNX | Buy Now | Regenxbio | $15.86 | 26.1% | RBC Capital | Luca Issi | → $20 | Reiterates | Sector Perform → Sector Perform | Get Alert |
08/29/2023 | RGNX | Buy Now | Regenxbio | $15.86 | 164.82% | Morgan Stanley | Vikram Purohit | $43 → $42 | Maintains | Overweight | Get Alert |
08/03/2023 | RGNX | Buy Now | Regenxbio | $15.86 | 246.78% | Chardan Capital | Daniil Gataulin | → $55 | Reiterates | → Buy | Get Alert |
07/12/2023 | RGNX | Buy Now | Regenxbio | $15.86 | 26.1% | RBC Capital | Luca Issi | → $20 | Reiterates | Sector Perform → Sector Perform | Get Alert |
06/20/2023 | RGNX | Buy Now | Regenxbio | $15.86 | 164.82% | Baird | Brian Skorney | → $42 | Initiates | → Outperform | Get Alert |
06/02/2023 | RGNX | Buy Now | Regenxbio | $15.86 | 164.82% | Baird | Brian Skorney | → $42 | Initiates | → Outperform | Get Alert |
05/09/2023 | RGNX | Buy Now | Regenxbio | $15.86 | 171.12% | Morgan Stanley | Vikram Purohit | $46 → $43 | Maintains | Overweight | Get Alert |
The latest price target for Regenxbio (NASDAQ: RGNX) was reported by Stifel on April 12, 2024. The analyst firm set a price target for $40.00 expecting RGNX to rise to within 12 months (a possible 155.10% upside). 21 analyst firms have reported ratings in the last year.
The latest analyst rating for Regenxbio (NASDAQ: RGNX) was provided by Stifel, and Regenxbio maintained their buy rating.
The last upgrade for Regenxbio Inc happened on March 8, 2024 when RBC Capital raised their price target to $35. RBC Capital previously had a sector perform for Regenxbio Inc.
There is no last downgrade for Regenxbio.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Regenxbio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Regenxbio was filed on April 12, 2024 so you should expect the next rating to be made available sometime around April 12, 2025.
While ratings are subjective and will change, the latest Regenxbio (RGNX) rating was a maintained with a price target of $0.00 to $40.00. The current price Regenxbio (RGNX) is trading at is $15.68, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.